ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The BCR-ABL1 fusion gene codes for a constitutively activated tyrosine kinase and can be inhibited by treatment with specific inhibitors, such as imatinib, which was able to improve the prognosis of CML from a mean overall survival of 3–7 years to a 10 year mean survival rate of more than 80% [2].